CompletedInterventionalPhase 2Updated Aug 21, 2018
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | NCT01080209 | Trialant
CompletedInterventionalPhase 2Updated Feb 20, 2015
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
ClinicalTrials.gov ID
NCT01080209
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
215Actual
Last Update Posted
Feb 20, 2015Estimated
Start Date
Feb 2010
Primary Completion Date
Feb 2014Actual
Completion Date
Feb 2014Actual
Brief Summary
This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Brimo PS DDS®
Sham
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Received the most recent sham or active study treatment of intravitreal Brimo PS DDS® no later than 36 months prior to entry into this study and have either completed their previous study, or have exited early from their previous study for any reason